

PRIOR AUTHORIZATION POLICY

POLICY: Oncology (Oral – Menin Inhibitor) – Komzifti Prior Authorization Policy

- Komzifti™ (ziftomenib capsules – Kura Oncology/Kyowa Kirin)

REVIEW DATE: 11/13/2025

OVERVIEW

Komzifti, a menin inhibitor, is indicated for the treatment of relapsed or refractory **acute myeloid leukemia (AML)** with a susceptible nucleophosmin 1 (*NPM1*) mutation, in adult patients who have no satisfactory alternative treatment options.¹

Guidelines

National Comprehensive Cancer Network (NCCN) AML guidelines (version 3.2026 – November 24, 2025) recommend Komzifti and Revuforj for patients with relapsed/refractory AML with *NPM1* mutation (both category 2A).² NCCN guidelines also has the following footnote: Komzifti is FDA approved for the treatment of adults with relapsed or refractory AML with a susceptible *NPM1* mutation with no satisfactory alternative treatment options.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Komzifti. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Komzifti is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Acute Myeloid Leukemia.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has relapsed or refractory disease; AND
 - C) The disease is positive for a susceptible nucleophosmin 1 (*NPM1*) mutation.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Komzifti is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Komzifti™ capsules [prescribing information]. San Diego, CA: Kura Oncology; November 2025.
-

2. The NCCN Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 3.2026 – November 24, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. . Accessed on November 25, 2025.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	11/13/2025
Update	11/26/2025: The overview section was updated to include updated guideline information.	--
